ALN-4324 / Alnylam - LARVOL DELTA

Uncovering the Structural Logic of Grb7: From Domain Mutagenesis to Therapeutic Implications in Cancer Signaling. (PubMed, J Mol Recognit) - "Grb7 is a member of the Grb7 protein family, which also includes Grb10 and Grb14...Truncating the distorted poly-proline region of Grb7 improved its model quality. Collectively, the results provide additional insight into the regulatory mechanisms of Grb7 and may aid in the development of Grb7-signaling dependent cancer therapeutics."

Journal • Oncology • GRB7

A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM (clinicaltrials.gov) - P1/2 | N=144 | Recruiting | Sponsor: Alnylam Pharmaceuticals | Phase classification: P1 ➔ P1/2 | N=84 ➔ 144 | Trial completion date: Jun 2026 ➔ Aug 2027 | Trial primary completion date: Jun 2026 ➔ Aug 2027

Enrollment change • Phase classification • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Phase 1 Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers (clinicaltrials.gov) - P1 | N=84 | Recruiting | Sponsor: Alnylam Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Obesity

A Phase 1 Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers (clinicaltrials.gov) - P1 | N=84 | Not yet recruiting | Sponsor: Alnylam Pharmaceuticals

New P1 trial • Obesity